Afatinib, a dual EGFR and HER2 inhibitor, led to increases in the response rates and PFS compared to methotrexate in patients with refractory or metastasis HNSCC when used as a single agent [96]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.